ArticleMolecular cancer research : MCR2011
Loss of Trop2 promotes carcinogenesis and features of epithelial to mesenchymal transition in squamous cell carcinoma.
Article in Molecular cancer research : MCR, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 64 citations in OpenAlex.
- METTL3-mediated m6A modification of TACSTD2 mRNA inhibits papillary thyroid cancer progression by activating the TNF signaling and blocking epithelial-mesenchymal transition.Scientific reports · 2025Article
- High Trop-2 expression in pulmonary sarcomatoid carcinoma reveals antibody-drug conjugate targeting Trop-2 is a promising therapeutic approach.Journal of translational medicine · 2025Article
- A multicenter study on TROP2 as a potential targeted therapy for extramammary Paget disease in Japan.Scientific reports · 2025Article
- Unveiling the future of breast cancer therapy: Cutting-edge antibody-drug conjugate strategies and clinical outcomes.Breast (Edinburgh, Scotland) · 2024Review
- The Tumor-Associated Calcium Signal Transducer 2 (TACSTD2) oncogene is upregulated in cystic epithelial cells revealing a potential new target for polycystic kidney disease.PLoS genetics · 2024Article
- TROP-2 is widely expressed in vulvar squamous cell carcinoma and represents a potential new therapeutic target.Journal of cancer research and clinical oncology · 2023Article
- Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan.NPJ breast cancer · 2023Article
- Antibody-Drug Conjugates in the Treatment of Urothelial Cancer.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2023Review
- Overview of Trop-2 in Cancer: From Pre-Clinical Studies to Future Directions in Clinical Settings.Cancers · 2023Review
- A non-mutatedFrontiers in oncology · 2023Article
- Therapeutic Antibodies in Cancer Treatment in the UK.International journal of molecular sciences · 2022Review
- Article
- EPCAM and TROP2 share a role in claudin stabilization and development of intestinal and extraintestinal epithelia in mice.Biology open · 2022Article
- TACSTD2 upregulation is an early reaction to lung infection.Scientific reports · 2022Article
- Trop-2 in Upper Tract Urothelial Carcinoma.Current oncology (Toronto, Ont.) · 2022Article
- Impact of Spatially Heterogeneous Trop-2 Expression on Prognosis in Oral Squamous Cell Carcinoma.International journal of molecular sciences · 2021Article
- DNA methylation of tumor associated calcium signal transducer 2 (TACSTD2) loci shows association with clinically aggressive renal cell cancers.BMC cancer · 2021Article
- Trop2 binding IGF2R induces gefitinib resistance in NSCLC by remodeling the tumor microenvironment.Journal of Cancer · 2021Article
- The role of Trop2 in prostate cancer: an oncogene, biomarker, and therapeutic target.American journal of clinical and experimental urology · 2021Article
- Mechanistic Insights into Trop2 Clustering on Lung Cancer Cell Membranes Revealed by Super-resolution Imaging.ACS omega · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
Abstract
Trop2, an oncogenic cell surface protein under investigation as a therapeutic target, is commonly overexpressed in several epithelial tumor types yet its function in tumor biology remains relatively unexplored. To investigate the role of Trop2 in epithelial carcinogenesis, we generated Trop2(-/-) mice, which are viable and possess a normal lifespan. Contrary to expectations, Trop2 loss fails to suppress keratinocyte transformation. Instead, ras-transformed Trop2(-/-) keratinocytes preferentially pass through an epithelial to mesenchymal transition (EMT) and form tumors with spindle cell histology. Furthermore, Trop2 loss renders Arf-null mice susceptible to the formation of biphasic sarcomatoid carcinomas containing both squamous and spindle cell components upon carcinogen exposure in an otherwise skin cancer-resistant strain (C57BL/6). Immortalized keratinocytes derived from Trop2(-/-)Arf(-/-) mice exhibit enhanced proliferative and migratory capacity as well as increased activation of mitogen-activated protein kinase and Src prior to transformation. The clinical relevance of these findings was supported by studying the molecular epidemiology of Trop2 in primary head and neck squamous cell carcinomas. This analysis revealed that Trop2 mRNA levels are decreased in a subset of tumors with features of EMT, and total loss of Trop2 protein expression is observed in the spindle cell component of sarcomatoid carcinomas. Therefore, while previous studies have emphasized the potential importance of Trop2 gain of function, these results uncover a role for Trop2 loss in tumorigenesis and the mesenchymal transdifferentiation observed in a subset of squamous cell carcinomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.